21-Gene Recurrence Score Assay Could Not Predict Benefit of Post-mastectomy Radiotherapy in T1-2 N1mic ER-Positive HER2-Negative Breast Cancer

21-Gene Recurrence Score Assay Could Not Predict Benefit of Post-mastectomy Radiotherapy in T1-2 N1mic ER-Positive HER2-Negative Breast Cancer

Introduction: It is still controversial whether post-mastectomy radiotherapy (PMRT) is necessary for women with T1-2 N1mic ER-positive HER2-negative breast cancer. The 21-gene recurrence score (RS) assay has been validated in T1-2 N1 breast cancer to be prognostic of locoregional recurrence (LRR) an...

Full description

Bibliographic Details
Main Authors: Wen-Wen Zhang, Qin Tong, Jia-Yuan Sun, Xin Hua, Zhi-Qing Long, Jia-Peng Deng, Yong Dong, Feng-Yan Li, Zhen-Yu He, San-Gang Wu, Huan-Xin Lin
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-04-01
Series:Frontiers in Oncology
Subjects:
breast cancer
micrometastasis of lymph nodes
post-mastectomy radiotherapy (PMRT)
21-gene recurrence score (RS) assay
surveillance
epidemiology
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.00270/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2019.00270/full

Similar Items